Pharma Mirror

SEPTEMBER 11, 2022

Bandung, W Java, Indonesia, PT Bio Farma, the holding company for state-owned pharmaceutical companies in Indonesia, announced a new milestone in the manufacturing of IndoVac, a Covid-19 vaccine brand it has developed since November 2021. Honesti Baasyir, the President Director of PT Bio Farma, said the company collaborated with Baylor College of Medicine, a private, independent health sciences centre in Houston, Texas to develop IndoVac, a recombinant protein subunit vaccine produced from yeast

Vaccination 130

Vaccination Vaccine Clinical Trials Clinical Trials 130

pharmaphorum

SEPTEMBER 11, 2022

A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has been shown to be more effective at improving progression-free survival than Bristol-Myers Squibb’s immunotherapy Yervoy in patients with advanced melanoma. It is the first time that a cell therapy for solid tumours has been tested in a phase 3 trial, and the first time that the approach has been directly compared with standard second-line immunotherapy in melanoma.

Trials 103

Trials Genetic Engineering Immune Response Engineer 103

NPR Health - Shots

SEPTEMBER 11, 2022

NPR's Ayesha Rascoe speaks with journalist Rachel Aviv about her book, "Strangers to Ourselves: Unsettled Minds and the Stories that Make Us." It explores the lives of six people with mental illness.

95

95

pharmaphorum

SEPTEMBER 11, 2022

Hard on the heels of a new $575 million partnership with GSK, US biotech SpringWorks Therapeutics has reported phase 3 data at ESMO that sets up regulatory filings for its lead drug nirogacestat in a rare and aggressive form of soft tissue cancer. The results of the DeFi trial of nirogacestat in 142 adults with progressing desmoid tumours showed a significant 71% improvement with the drug on progression-free survival (PFS) compared to placebo, with an overall response rate of 41% and 8%, respect

Drugs 52

Drugs Trials Antibody Production 52

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Clinical Research

NPR Health - Shots

SEPTEMBER 11, 2022

NPR's Ayesha Rascoe speaks to Nsikan Akpan, health and science editor at WNYC/Gothamist, about the poliovirus emergecy disaster declaration in New York state.

65

65

pharmaphorum

SEPTEMBER 11, 2022

Bristol-Myers Squibb’s deucravacitinib– one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe plaque psoriasis. The US FDA has cleared the first-in-class tyrosine kinase 2 (Tyk2) inhibitor as Sotyktu , and BMS says it now plans to launch the new drug later this month, aiming to mount a challenge to Amgen’s $2.3 billion oral psoriasis therapy Otezla (apremilast).

FDA Approval 52

FDA Approval Sales Drugs Marketing 52

Drug Patent Watch

SEPTEMBER 11, 2022

Annual Drug Patent Expirations for BREO+ELLIPTA Breo Ellipta is a drug marketed by Glaxo Grp Ltd and is included in one NDA. It is available from two suppliers. There are…. The post New patent expiration for Glaxo Grp drug BREO ELLIPTA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

SEPTEMBER 11, 2022

Annual Drug Patent Expirations for ANORO+ELLIPTA Anoro Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA. It is available from one supplier. There are fifteen patents…. The post New patent expiration for Glaxosmithkline drug ANORO ELLIPTA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

SEPTEMBER 11, 2022

Annual Drug Patent Expirations for TRELEGY+ELLIPTA Trelegy Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA. It is available from one supplier. There are fifteen patents…. The post New patent expiration for Glaxosmithkline drug TRELEGY ELLIPTA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

SEPTEMBER 11, 2022

Annual Drug Patent Expirations for ORAVIG Oravig is a drug marketed by Galt Pharms and is included in one NDA. It is available from one supplier. There are three patents…. The post New patent expiration for Galt Pharms drug ORAVIG appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

Clinical Trials

Drug Patent Watch

SEPTEMBER 11, 2022

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Sweden. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Sweden? appeared first on DrugPatentWatch - Make Better Decisions.

52

52